CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. - Wikidata - awgldk - TriplyDB

CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy.

CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy.

http://www.wikidata.org/entity/Q38068539

about

Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism Genomics into Healthcare: the 5th Pan Arab Human Genetics Conference and 2013 Golden Helix Symposium Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes.Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity.Statins and breast cancer prognosis: evidence and opportunities.Pharmacogenetic Foundations of Therapeutic Efficacy and Adverse Events of Statins.Multigene predictors of tacrolimus exposure in kidney transplant recipients.Donor PPARα Gene Polymorphisms Influence the Susceptibility to Glucose and Lipid Disorders in Liver Transplant Recipients: A Strobe-Compliant Observational Study Association of single nucleotide polymorphisms in IL8 and IL13 with sunitinib-induced toxicity in patients with metastatic renal cell carcinoma.Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.Genotype-guided tacrolimus dosing in African-American kidney transplant recipients.Cytochrome P450 3A4*22, PPAR-α, and ARNT polymorphisms and clopidogrel response Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients Optimization of Clonazepam Therapy Adjusted to Patient's CYP3A Status and NAT2 Genotype.Polymorphisms in drug-metabolizing enzymes and steady-state exemestane concentration in postmenopausal patients with breast cancer.Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.Genes and beans: pharmacogenomics of renal transplant.Pharmacogenetics of drug metabolizing enzymes in the United Kingdom population: review of current knowledge and comparison with selected European populations.Effect of CYP3A4*22, CYP3A5*3, and CYP3A combined genotypes on tamoxifen metabolism.Response to Impact of CYP3A4 Genotype on Voriconazole Exposure - New Insights into the Contribution of CYP3A4*22 to Metabolism of Voriconazole.Synergistic disruption of ERα/HER2 crosstalk by endoxifen and lapatinib in breast cancer cells.The genetic basis of antiplatelet and anticoagulant therapy: A pharmacogenetic review of newer antiplatelets (clopidogrel, prasugrel and ticagrelor) and anticoagulants (dabigatran, rivaroxaban, apixaban and edoxaban).Kinase inhibitor pharmacokinetics: comprehensive summary and roadmap for addressing inter-individual variability in exposure.Genetic Polymorphisms Affecting the Pharmacokinetics of Antiretroviral Drugs.A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach.Effects of EPHX1 and CYP3A4 polymorphisms on carbamazepine metabolism in epileptic patients.Effects of EPHX1 and CYP3A4*22 genetic polymorphisms on carbamazepine metabolism and drug response among Tunisian epileptic patients.Irinotecan-induced muscle twitching from a possible drug interaction: A case report.Effects of Genetic Polymorphisms of Cytochrome P450 Enzymes and MDR1 Transporter on Pantoprazole Metabolism and Helicobacter pylori Eradication.Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation.Tamoxifen-associated hot flash severity is inversely correlated with endoxifen concentration and CYP3A4*22.The association among cytochrome P450 3A, progesterone receptor polymorphisms, plasma 17-alpha hydroxyprogesterone caproate concentrations, and spontaneous preterm birth.Precision medicine for HIV: where are we?Genetic and Clinical Factors Are Associated With Statin-Related Myotoxicity of Moderate Severity: A Case-Control Study.Rapid decline in insulin antibodies and glutamic acid decarboxylase autoantibodies with ibrutinib therapy of chronic lymphocytic leukaemia.Pharmacogenetic considerations for HIV treatment in different ethnicities: an update.The combination of pharmacogenetic and pharmacokinetic analyses to optimize clomipramine dosing in major depression: a case report.Pharmacogenetics of trazodone in healthy volunteers: association with pharmacokinetics, pharmacodynamics and safety.Polymorphisms in CYP1A1 and CYP3A5 Genes Contribute to the Variability in Granisetron Clearance and Exposure in Pregnant Women with Nausea and Vomiting.Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients.

P2860

Q28552997-3446608F-671B-4474-8AC1-26AD10886B0F Q28654679-85CE1B36-08FA-4A37-BA32-EF98DF367077 Q30357429-4F44F1BB-0515-4346-92AA-A0CE1FD82746 Q33434697-BE3BDDF7-6A72-497B-AFAD-480BCA102FB9 Q34206487-B86B66B8-77BD-4F5E-B3E4-9C84146204F2 Q34680467-A2F4C358-0A6D-45D8-AB18-554453AF5F44 Q35924246-E122B8EA-B5A9-4298-A367-2E47A0D9CEF3 Q36194349-BB859995-1390-46B1-B6D0-55D1E4C4653C Q36275134-C2C33D27-3C37-4308-AA3A-BA67A91E2642 Q36410101-8CF24A58-5888-45AA-A655-0795E58DCA86 Q37009025-05BB23E5-B8A4-44B1-9254-B87C73C919FF Q37390889-88D1A369-1F33-46E7-9B22-FC3AF9AF0A6E Q37439873-665D8922-B54F-45EE-8152-4BCB83F3C64F Q37547290-DB3A3519-6EDF-4F48-AD14-0E399A006064 Q37662607-B7402F75-239F-4C3B-BD62-11054C12BA1A Q37678060-6CDA9B51-7587-4D99-BB83-5D5F49C3D3CF Q38104742-D9CB6BDE-6DA8-4F4A-ACAD-8D7861DD3CC0 Q38388873-91F525CF-B71A-478C-89B9-239B670714CC Q38604479-DA3CAF5D-5EDD-4D60-8563-F2F932BBCE6E Q38635370-30B43126-EFB0-44BA-8D52-EB3B2EF7A3AA Q38726658-B6C9BF05-4E8E-431F-8889-6E99C02FA925 Q38750444-7534D840-9E24-45C1-A1FA-E1950E404D17 Q38937228-54E141BF-BFA7-41E0-B994-3A376BE65CD9 Q38957969-F4C788A1-C612-41CA-AD26-A9B06BF3A5C7 Q39041618-CC21583E-4621-41ED-A79B-3E2AA1C1F9A1 Q39313577-12C9F166-4086-40B9-81BE-42DC338E6FC2 Q39700743-05E2A7BD-C1CA-4F25-9F8F-615D0641D732 Q40107303-6740A2C1-A55A-40F6-8279-184C798A300F Q40471212-0EC78DCD-B138-4B03-9568-F65B831D6BDC Q42215557-4EA1F7D2-48BA-4917-BE82-95594216B868 Q44899685-A3DA6E85-6953-457D-A72E-279800340B7E Q46304188-F74173EF-9C88-42B9-BFB2-72BB34402025 Q47569821-ED1DDFDB-885D-47BA-BBF3-4EBA91659987 Q47676842-BE4CE0C7-A54E-41AE-8A0A-B4E946E74D85 Q47820958-003F863D-0FA0-4BAA-898E-ABA98A0B30A0 Q47906608-D1387FB0-F2C0-40BC-97E6-C69E933A886F Q48037601-9902DE57-AA45-4689-B10F-B283B8A99C2D Q50072074-1D20FCCB-F95D-44E0-9169-96A31EC43BDC Q51347270-B929F060-1D41-46C1-B5C6-ED7DEBE2E99F Q53581485-103DD49B-74CE-42D7-A121-80487F8473B3

P2860

CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy.

http://www.wikidata.org/entity/Q38068539

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

CYP3A4*22: promising newly ide ...... personalizing pharmacotherapy.

@en

type

label

CYP3A4*22: promising newly ide ...... personalizing pharmacotherapy.

@en

prefLabel

CYP3A4*22: promising newly ide ...... personalizing pharmacotherapy.

@en

P1433

Q38068539-F93BD992-3746-4C9E-881A-84C0FC1D00DE

P1476

Q38068539-0027B235-1186-492A-9BF1-7EC590F53B00

P2093

Q38068539-2E9172B7-3024-44F5-8AD6-2C43793BC134

Q38068539-40618DA3-8555-444F-B76F-C7EDB294E09C

Q38068539-8CCA3B22-E528-4C5B-9D14-060BCF622B17

Q38068539-BC467E58-EE80-4B1E-BCFA-FF20CB6D07E5

Q38068539-E317EA94-1437-4A9E-BE74-A4B34D011CF6

P2860

Q38068539-0360F55D-3D50-45EF-BCB1-F874571B14F4

Q38068539-06338539-4944-48B9-A496-039C94BEB386

Q38068539-09CCEC27-DC08-44B6-9F8B-3F6E569E9579

Q38068539-0C978945-1F8A-4C03-B9F7-FB3877116604

Q38068539-0DEC98AA-D01D-4F8A-9405-282B29079B3F

Q38068539-1060F47A-D7DC-4F23-B2AB-95549E9D1549

Q38068539-18645B40-D146-4E3F-BC6D-7021EAE00B44

Q38068539-2AFBCEBC-AE9C-4675-B1CE-3EA7AA83FD72

Q38068539-2C6FA287-EA9D-432B-972E-170DD0665A4D

Q38068539-309FFA1E-1742-4BCC-A2FB-941BA116D209

P304

Q38068539-72CDEE7B-9C62-4951-8AC1-922EE7E21863

P31

Q38068539-A120CEC5-658B-4EF3-BCAB-C163C79411D1

P356

Q38068539-78D7ABBB-C115-4CC9-8C8B-D513CE5F5C1C

P433

Q38068539-580F518F-5D60-4392-8371-FD56F1F34998

P478

Q38068539-E39943E7-F176-47DB-9954-6199F556DA91

P577

Q38068539-7A4BF554-4516-4883-A3E3-F4718106D98F

P5875

Q38068539-125ECCF7-A4D5-4EAA-8541-BE7E74F1D761

P698

Q38068539-129FFABE-4255-42B5-822F-8AFFBE38B830

P921

Q38068539-37E6B070-EF77-4BBE-90EB-1EC829B11B58

P356

P1433

Pharmacogenomics

P1476

CYP3A4*22: promising newly ide ...... personalizing pharmacotherapy.

@en

P2093

Dennis A Hesselink

http://www.w3.org/2001/XMLSchema#string

Laure Elens

http://www.w3.org/2001/XMLSchema#string

Ron H N van Schaik

http://www.w3.org/2001/XMLSchema#string

Teun van Gelder

http://www.w3.org/2001/XMLSchema#string

Vincent Haufroid

http://www.w3.org/2001/XMLSchema#string

P2860

CYP3A4 and CYP3A5 genotyping by Pyrosequencing

Genetic contribution to variable human CYP3A-mediated metabolism

CYP3A phenotypes and genotypes in North Indians

Functionally defective or altered CYP3A4 and CYP3A5 single nucleotide polymorphisms and their detection with genotyping tests

The cytochrome P450 superfamily: biochemistry, evolution and drug metabolism in humans

Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines

Cytochrome P450 3A: ontogeny and drug disposition.

Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes.

Effect of CYP3A and ABCB1 single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part I.

Pharmacogenetics: from bench to byte--an update of guidelines.

P304

47-62

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2217/PGS.12.187

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

14

http://www.w3.org/2001/XMLSchema#string

P577

2013-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

233956537

http://www.w3.org/2001/XMLSchema#string

P698

23252948

http://www.w3.org/2001/XMLSchema#string

P921

pharmacotherapy